Application of the quartz crystal microbalance to nanomedicine

Journal of Biomedical Nanotechnology

Volumn 5, Issue 6, 2009, Pages 669-675

  Hunter, Alan Christy ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Acoustic sensor technology; Apoptosis; Complement activation; Nanomedicine; Nanoparticle; Quartz crystal microbalance; SiRNA; Surface decoration

Indexed keywords

ACOUSTIC SENSORS; APOPTOSIS; COMPLEMENT ACTIVATION; NANOMEDICINE; NANOMEDICINES; SURFACE DECORATION;

ACOUSTIC DEVICES; ACOUSTICS; BINDING ENERGY; CELL DEATH; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; OXIDE MINERALS; PIEZOELECTRIC DEVICES; QUARTZ; RNA;

QUARTZ CRYSTAL MICROBALANCES;

DOCETAXEL; DOXORUBICIN; LIPOSOME; NANOCARRIER; PACLITAXEL; SELENIUM;

APOPTOSIS; COMPLEMENT SYSTEM; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; MICELLE; MICROENVIRONMENT; NANOMEDICINE; PERFORMANCE; QUARTZ CRYSTAL MICROBALANCE; REVIEW;

ACOUSTICS; BIOSENSING TECHNIQUES; CRYSTALLIZATION; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; MICRO-ELECTRICAL-MECHANICAL SYSTEMS; NANOMEDICINE; QUARTZ; TRANSDUCERS;

EID: 76749120533     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1083     Document Type: Review

References (74)

1. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Nanomedicine: Current status and future prospects. FASEB J. 19, 311 (2005).
2. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Long-circulating and target-specific nanoparticles: Theory to practice. Pharm. Rev. 53, 283 (2001).
3. A. C. Hunter, Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Del. Rev. 58, 1523 (2006).
4. S. M. Moghimi and A. R. Rajabisiahboomi, Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. Prog. Biophys. Mol. Biol. 65, 221 (1996).
5. J. K. Gbadamosi, A. C. Hunter, and S. M. Moghimi, PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 532, 338 (2002).
6. S. M. Moghimi, A. C. Hunter, C. M. Dadswell, S. Savay, C. R. Alving, and J. Szebeni, Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta Mol. Basis Dis. 1689, 103 (2004).
7. S. M. Moghimi and J. C. Murray, Poloxamer-188 revisited: A potentially valuable immune modulator. J. Natl. Cancer Inst. 88, 766 (1996).
8. A. C. Hunter and S. M. Moghimi, Therapeutic synthetic polymers: A game of russian roulette. Drug Discov. Today 7, 998 (2002).
9. S. M. Moghimi and A. C. Hunter, Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trend Biotechnol. 18, 412 (2000).
10. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J. M. Metselaar, G. Storm, A. Chanan-Khan, L. Liebes, F. M. Muggia, R. Cohen, Y. Barenholz, and C. R. Alving, Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: Experimental and clinical studies. J. Liposome Res. 12, 165 (2002).
11. S. M. Moghimi and I. Hamad, Liposome-mediated triggering of complement cascade. J. Liposome Res. 18, 195 (2008).
12. I. Hamad, A. C. Hunter, J. Szebeni, and S. M. Moghimi, Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225 (2008).
13. S. M. Moghimi, P. Symonds, J. C. Murray, A. C. Hunter, G. Debska, and A. Szewczyk, A two-stage poly(ethyleneimine)-mediated cytotoxicity: Implications for gene transfer/therapy. Mol. Ther. 11, 990 (2005).
14. P. Symonds, J. C. Murray, A. C. Hunter, G. Debska, A. Szewczk, and S. M. Moghimi, Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Lett. 579, 6191 (2005).
15. 1H NMR study. Biochimica Biphysica Acta-Biomembranes 1374, 9 (1998).
16. J. A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, and I. Ahmad, Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharmaceutics Biopharmaceutics 59, 177 (2005).
17. G. S. Kwon and T. Okano, Polymeric micelles as new drug carriers. Adv. Drug Del. Rev. 21, 107 (1996).
18. M.-C. Jones, H. Gao, and J.-C. Leroux, Reverse polymeric micelles for pharmaceutical applications. J. Control Rel. 132, 208 (2008).
19. O. Al-Hanbali, N. M. Onwuzo, K. J. Rutt, C. M. Dadswell, S. M. Moghimi, and A. C. Hunter, Modification of the stewart biphasic colorimetric assay for stable and accurate quantitative determination of pluronic and tetronic block copolymers for application in biological systems. Anal. Biochem. 361, 287 (2007).
20. S. J. Braunhut, D. McIntosh, E. Vorotnikova, T. Zhou, and K. A. Marx, Detection of apoptosis and drug resistance of human breast cancer cells to taxane treatments using quartz crystal microbalance biosensor technology. Assay Drug Dev. Technol. 3, 77 (2005).
21. T. Deng, J.-S. Li, H. Wang, G.-L. Shen, and R.-Q. Yu, Piezoelectric immunoassay for complement C4 based on a Nafion-modified interface for antibody immobilization. J. Immunol. Method 299, 1 (2005).
22. A. Janshoff, H. J. Galla, and C. Steinnem, Piezoelectric mass-sensing devices as biosensors-An alternative to optical biosensors? Angew. Chem. Int. Edit. 39, 4004 (2000).
23. L. Pastorino, F. Caneva, M. Giacomini, and C. Ruggiero, Development of a piezoelectric imminosensor for measurement of paclitaxel. J. Immunol. Method 313, 191 (2006).
24. 2. Langmuir 22, 3313 (2006).
25. E. Reimhult, B. Kasemo, and F. Höök, Rupture pathway of phosphatidylcholine liposomes on silicon dioxide. Int. J. Mol. Sci. 10, 1683 (2009).
26. J. Elsom, M. I. Lethem, G. D. Rees, and A. C. Hunter, Novel quartz crystal microbalance based biosensor for detection of oral epithelial cell-micropartical interaction in real-time. Biosens. Bioelectron. 23, 1259 (2008).
27. M. A. Cooper and C. Whalen, Profiling molecular interactions using label-free acoustic screening. Drug Discov. Today: Technologies 2, 241 (2005).
28. B. Godber, M. Frogley, M. Rehak, A. Sleptsov, K. S. J. Thompson, Y. Uludag, and M. A. Cooper, Profiling of molecular interactions in real time using acoustic detection. Biosen. Bioelectron. 22, 2382 (2007).
29. M. A. Cooper, Non-optical screening platforms: The next wave in label-free screening. Drug Discov. Today 11, 1068 (2006).
30. M. Andersson, J. Andersson, A. Sellborn, M. Berglin, B. Nilsson, and H. Elwing, Quartz crystal microbalance-with dissipation monitoring (QCM-D) for real time measurements of blood coagulation density and immune complement activation on artificial surfaces. Biosens. Bioelectron. 21, 79 (2005).
31. V. Schmidt, C. Giacomelli, C. Gounou, J. Lai-Kee-Him, A. R. Brisson, and R. Borsali, Formation of Annexin-A5 Protein/block copolymer micelle complexes: QCM-D and PAGE experiments. Langmuir 24, 12189 (2008).
32. M. A. Cooper, Biosensing using rupture event scanning (REVS)™. Meas. Sci. Technol. 14, 1888 (2003).
33. M. Liebau, G. Bendas, U. Rothe, and R. H. H. Neubert, Adhesive interactions of liposomes with supported planar bilayers on QCM as a new adhesion model. Sens. Actuators, B 47, 239 (1998).
34. M. Liebau, A. Hildebrand, and R. H. H. Neubert, Bioadhesion of supramolecular structures at supported planar bilayers as studied by the quartz crystal microbalance. Eur. Biophys. J. 30, 42 (2001).
35. A. Hildebrand, A. Schaedlich, U. Rothe, and R. H. H. Neubert, Sensing specific adhesion of liposomal and micellar systems with attached carbohydrate recognition structures at lectin surfaces. J. Colloid Interface Sci. 249, 274 (2002).
36. S. Morita, M. Nukui, and R. Kuboi, Immobilization of liposomes onto quartz crystal microbalance to detect interaction between liposomes and proteins. J. Colloid Interface Sci. 298, 672 (2006).
37. S. M. Moghimi and A. C. Hunter, Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carrier Sys. 18, 527 (2001).
38. S. M. Moghimi and J. Szebeni, Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonisation and protein-binding properties. Prog. Lipid Res. 42, 463 (2003).
39. 2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochimica Biophysica Acta Biomembr. 1778, 51 (2008).
40. P. Vermette, L. Meagher, E. Gagnon, H. J. Griesser, and C. J. Doillon, Immobilized liposome layers for drug delivery applications: Inhibition of angiogenesis. J. Control Rel. 80, 179 (2002).
41. P. Vermette, H. J. Griesser, P. Kambouris, and L. Meagher, Characterization of surface-immobilized layers of intact liposomes. Biomacromolecules 5, 1496 (2004).
42. H. Brochu and P. Vermette, Liposome layers characterized by quartz crystal microbalance measurements and multirelease delivery. Langmuir 23, 7679 (2007).
43. 2-muscarinic receptors. Proteiomics 9, 2052 (2009).
44. Y. Rojanasakul, Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug Del. Rev. 18, 115 (1996).
45. I. Brigger, C. Dubernet, and P. Couvreur, Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 54, 631 (2002).
46. K. Zwiorek, C. Bourquin, J. Battiany, G. Winter, S. Endres, G. Hartmann, and C. Conrad, Delivery by cationic gelatine nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 25, 551 (2008).
47. S. Hamilton and E. Harth, Molecular dendritic transporter nanoparticle vectors provide efficient intracellular delivery of peptides. ACS Nano 3, 402 (2009).
48. X. L. Zhang, C. G. Koh, B. Yu, S. J. Liu, L. Z. Piao, G. Marcucci, R. J. Lee, and L. J. Lee, Transferrin receptor targeted lipopolyplexes of delivery of antisense oligonucleotide G3139 in a murine K562 xenograft model. Pharm. Res. 26, 1516 (2009).
49. K. A. Howard, Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Del. Rev. 61, 710 (2009).
50. S. K. Arya, P. R. Solanki, M. Datta, and B. D. Malhotra, Recent advances in self-assembled monolayers based biomolecular electronic devices. Biosens. Bioelectron. 24, 2810 (2009).
51. K. Sakai, E. G. Smith, G. B. Webber, M. Baker, E. J. Wanless, V. Bütün, S. P. Armes, and S. Biggs, Characterizing the pH-responsive behaviour of thin films of diblock copolymer micelles at the silica/aqueous solution interface. Langmuir 22, 8435 (2006).
52. Y.-K. Oh and T. G. Park, siRNA delivery systems for cancer treatment. Adv. Drug Del. Rev. 61, 850 (2009).
53. A. M. Gewirtz, On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J. Clin. Invest. 117, 3612 (2007).
54. M. A. Behlke, Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644 (2006).
55. S. Spagnou, A. D. Miller, and M. Keller. Lipidic carriers of siRNA: Differences in the formulation, cellular uptake and delivery with Plasmid DNA. Biochemistry 43, 13348 (2004).
56. A. Alshamsan, A. Haddadi, V. Incani, J. Samuel, A. Lavasanifar, and H. Uludag, Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol. Pharmaceutics 6, 121 (2009).
57. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Rel. 114, 100 (2006).
58. A. Akinc, A. Zumbuehl, M. Goldberg, E. S. Leshchiner, V. Busini, N. Hossain, S. A. Bacallado, D. N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constein, A. de Fougerolles, J. R. Dorkin, K. N. Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K. G. Rajeev, D. W. Y. Sah, J. Soutschek, I. Toudjarska, H.-P. Vornlocher, T. S. Zimmermann, R. Langer, and D. G. Anderson, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotech. 26, 561 (2008).
59. V. Heitmann, B. Reiß, and J. Wegener, The quartz crystal microbalance in cell biology: Basics and applications. Springer Ser. Chem. Sens. Biosens. 5, 303 (2007).
60. M. A. Cooper and V. T. Singleton, A survey of the 2001 to 2005 quartz crystal microbalance biosensor literature: Applications of acoustic physics to the analysis of biomarker interactions. J. Mol. Recognit. 20, 154 (2007).
61. K. A. Marx, T. Zhou, M. Warren, and S. J. Braunhut, Quartz crystal microbalance study of endothelial cell number dependent differences in initial adhesion and steady-state behaviour: Evidence for cell-cell cooperative initial adhesion and spreading. Biotechnol. Prog. 19, 987 (2003).
62. K. A. Marx, T. Zhou, A. Montrone, D. McIntosh, and S. J. Braunhut, Quartz crystal microbalance biosensor study of endothelial cells and their extracellular matrix following cell removal: Evidence for transient cellular stress and viscoelastic changes during detachment and the elastic behaviour of the pure matrix. Anal. Biochem. 343, 23 (2005).
63. K. A. Marx, T. Zhou, A. Montrone, D. McIntosh, and S. J. Braunhut, A comparative study of the cytoskeleton binding drugs nocodazole and taxol with a mammalian cell quartz crystal microbalance biosensor: Different dynamic responses and energy dissipation effect. Anal. Biochem. 361, 77 (2007).
64. K. A. Marx, T. Zhou, A. Montrone, H. Schultz, and S. J. Braunhut, A quartz crystal microbalance cell biosensor. Detection of microtubule alterations in living cells at nM nocodazole concentrations. Biosens. Bioelectron. 16, 773 (2001).
65. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
66. X.-L. Wei, Z.-H. Mo, B. Li, and J.-M. Wei, Disruption of HepG2 cell adhesion by gold nanoparticle and paclitaxel disclosed by in situ QCM measurement. Colloid Surf. B: Biointerface 59, 100 (2007).
67. L. Tan, X. Jia, X. Jiang, Y. Zhang, H. Tang, S. Yao, and Q. Xie, In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with quartz crystal microbalance. Biomaterials 24, 2268 (2009).
68. J. Szebeni, Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 216, 106 (2005).
69. J. Szebeni, J. Baranyi, S. Savay, M. Bodo, J. Milosevits, C. R. Alving, and R. Bunger, Complement activation-related cardiac anaphylaxis in pigs: Role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol-Heart and Circ. Physiol. 290, H1050 (2006).
70. S. M. Moghimi and T. L. Andresen, Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines. Mol. Immunol. 46, 1571 (2009).
71. J. Szebeni and S. M. Moghimi, Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions. J. Liposome Res. 19, 85 (2009).
72. J. Andersson, K. N. Ekdahl, J. D. Lambris, and B. Nilsson, Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials 26, 1477 (2005).
73. A. Sellborn, M. Andersson, C. Fant, C. Gretzer, and H. Elwing, Methods for research on immunocomplement activation on modified sensor surfaces. Colloid Surf. B: Biointerfaces 27, 295 (2003).
74. M. M. Markiewski, R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, G. Gerard, G. Coukos, and J. D. Lambris, Modulation of the antitumour immune response by complement. Nat. Immunol. 9, 1225 (2008).